🔗 Permalink

Inventor profile of:

Steve Holmes

City:

Cambridge

Country:

United Kingdom

Published Applications:

Last publication date:

2026-04-16

Top Assignees for applications by Steve Holmes

The entities that hold a legal rights for patent applications filed by inventor Holmes Steve:

Kymab Limited 18 Cambridge, United Kingdom
BRISTOL-MYERS SQUIBB COMPANY 6 Princeton, NJ United States
Domantis Limited 5 Brentford, Middlesex, United Kingdom
Kymab Limited 4 , United Kingdom
DOMANTIS LIMITED 3 Brentford, United Kingdom
Domantis Ltd. 3 Brentford, United Kingdom
Domantis Limited 3 , United Kingdom
Domantis Limited 2 Middlesex, United Kingdom
Domants Limited 1 Cambridge, United Kingdom
Bristol-Meyers Squibb Company 1 Princeton, NJ United States
Glaxo Group Limited 1 , United Kingdom
GLAXO GROUP LIMITED 1 Greenford, Middlesex, United Kingdom

Recent patent applications by Holmes Steve

Steve Holmes from Cambridge, GB has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-04-16

US20260103533A1

Chemistry; metallurgy

ANTI-OPG ANTIBODIES

#2 | 2025-08-21

US20250263492A1

Chemistry; metallurgy

ANTIBODIES, USES & METHODS

#3 | 2024-04-25

US20240132605A1

Chemistry; metallurgy

ANTIBODIES, USES & METHODS

#4 | 2024-01-25

US20240026020A1

Chemistry; metallurgy

ANTI-OPG ANTIBODIES

#5 | 2023-08-31

US20230272097A1

Chemistry; metallurgy

THERAPEUTIC ANTIBODIES

#6 | 2022-11-24

US20220372153A1

Chemistry; metallurgy

SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD

#7 | 2021-12-23

US20210395378A1

Chemistry; metallurgy

Antibodies, uses and methods

#8 | 2021-03-25

US20210087287A1

Chemistry; metallurgy

Nucleic acids encoding anti-OX40L antibodies

#9 | 2021-02-18

US20210047414A1

Chemistry; metallurgy

Compositions monovalent for CD28 binding and methods of use

#10 | 2019-11-21

US20190352413A1

Chemistry; metallurgy

Anti-OPG antibodies

#11 | 2019-09-12

US20190276547A1

Chemistry; metallurgy

ANTIBODIES, USES & METHODS

#12 | 2018-05-24

US20180142023A1

Chemistry; metallurgy

Compositions monovalent for CD28 binding and methods of use

#13 | 2017-11-16

US20170327587A1

Chemistry; metallurgy

Methods of treating comprising administering anti-OX40L antibodies

#14 | 2017-11-16

US20170327586A1

Chemistry; metallurgy

Synergistic combinations of OX40L antibodies for the treatment of GvHD

#15 | 2017-11-09

US20170320956A1

Chemistry; metallurgy

ANTI-LIGHT ANTIBODIES

#16 | 2017-10-12

US20170291951A1

Chemistry; metallurgy

Anti-LIGHT antibodies

#17 | 2017-09-14

US20170260279A1

Chemistry; metallurgy

Synergistic combinations of OX40L antibodies for the treatment of GvHD

#18 | 2017-07-27

US20170210814A1

Chemistry; metallurgy

METHODS FOR TARGETING PULMONARY DISEASES WITH AGENTS THAT BIND A TARGET IN PULMONARY TISSUE

#19 | 2017-02-16

US20170044250A1

Chemistry; metallurgy

Methods of treating SLE with anti-OX40L antibodies

#20 | 2017-02-09

US20170037137A1

Chemistry; metallurgy

SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD

#21 | 2017-01-05

US20170002083A1

Chemistry; metallurgy

Anti-hOX40L antibodies, uses, and methods

#22 | 2016-12-22

US20160368997A1

Chemistry; metallurgy

Anti-OX40L antibodies and methods of treating graft versus host disease

#23 | 2016-09-15

US20160264675A1

Chemistry; metallurgy

Synergistic combinations of OX40L antibodies for the treatment of GVHD

#24 | 2016-09-06

US14935937

Chemistry; metallurgy

Anti-human OX40L antibodies and methods of treating graft versus host disease with the same

#25 | 2016-01-12

US14811163

Chemistry; metallurgy

Anti-human OX40L antibodies

#26 | 2015-10-22

US20150299321A1

Chemistry; metallurgy

Compositions monovalent for CD28 binding and methods of use

#27 | 2015-09-22

US14700896

Chemistry; metallurgy

Anti-human OX40L antibodies and methods of treatment

#28 | 2013-11-21

US20130309227A1

Human necessities

Methods for targeting pulmonary diseases with agents that bind a target in pulmonary tissue

#29 | 2013-05-02

US20130109846A1

Chemistry; metallurgy

Compositions monovalent for CD28 binding and methods of use

#30 | 2013-02-14

US20130041136A1

Chemistry; metallurgy

LIGANDS THAT HAVE BINDING SPECIFICITY FOR EGFR AND/OR VEGF AND METHODS OF USE THEREFOR

#31 | 2012-10-04

US20120253017A1

Human necessities

STEM CELL TARGETING

#32 | 2012-08-09

US20120201814A1

Chemistry; metallurgy

Compositions monovalent for CD28 binding and methods of use

#33 | 2012-05-24

US20120129778A1

Chemistry; metallurgy

Ligands that bind TGF-β receptor RII

#34 | 2012-05-10

US20120114651A1

Human necessities

Methods for targeting pulmonary diseases with agents that bind a target in pulmonary tissue

#35 | 2010-02-11

US20100034831A1

Human necessities

Agents that bind a target in pulmonary tissue for targeting respiratory diseases

#36 | 2010-02-04

US20100028354A1

Chemistry; metallurgy

Compositions monovalent for CD28 binding and methods of use

#37 | 2009-03-26

US20090081233A1

Chemistry; metallurgy

Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor

#38 | 2008-09-25

US20080233130A1

Chemistry; metallurgy

Ligand that has binding specificity for IL-4 and/or IL-13

#39 | 2008-09-25

US20080233129A1

Chemistry; metallurgy

Ligand that has binding specificity for IL-4 and/or lL-13

#40 | 2007-05-10

US20070104710A1

Chemistry; metallurgy

Ligand that has binding specificity for IL-4 and/or IL-13

#41 | 2007-01-04

US20070003549A1

Chemistry; metallurgy

Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor

InventorID:

92270 ⎘